Laxxon Medical
Pipeline
As of November 2026
Laxxon develops its own Advanced Patented Generics with SPID®: established active ingredients in new oral dosage forms, for the FDA 505(b)(2) pathway in the US and the hybrid application in the EU. The lead program is LXM.2, an oral GLP-1 RA.
Focus program · LXM.2
An oral GLP-1 RA, enabled by SPID® technology
The challenge
Most GLP-1 RA medicines are peptides, and peptide medicines usually have to be injected. Peptides are large molecules that pass poorly through the gut wall and are broken down by enzymes and bacteria in the gastrointestinal tract. As a result, only a small fraction of an oral dose reaches the bloodstream (low oral bioavailability).
The approach
SPID® prints without heat, so heat-sensitive active ingredients such as peptides stay intact. SPID®-printed dosage forms are designed to protect the peptide from enzymes and bacteria on its way through the gastrointestinal tract and to release it where it can be absorbed, with the aim of improving oral bioavailability. For LXM.2, Laxxon is developing SPID®-printed oral GLP-1 RA microtablets.
The status
In preclinical development, with Phase 1 planned for 2027.
Sources: Drucker DJ, Advances in oral peptide therapeutics, Nature Reviews Drug Discovery 2020;19:277–289; company information and press release of October 21, 2026.
How SPID® works for peptides →Disclosed programs
Focus program
LXM.2
- Indication
- Obesity and metabolic disease (oral GLP-1 RA)
- Stage
- Phase 1 planned (2027)
- Notes
- SPID®-printed oral GLP-1 RA microtablets (press release, October 21, 2026)
LXM.5
- Indication
- Parkinson's disease (levodopa/carbidopa)
- Stage
- Phase 1 in preparation
- Notes
- First dosing planned for early 2027; published animal PK data on the Platform page
Partner program
LXM.8
- Indication
- Chronic weight management (enobosarm)
- Stage
- Phase 1 completed
- Notes
- Formulation selected by the partner after a clinical PK study (partner's press release, August 11, 2025)
Six further programs are in preclinical development; details are not disclosed.
Partnering on pipeline assets
Laxxon is open to licensing and co-development partnerships for individual assets.
